171 related articles for article (PubMed ID: 37916907)
1. Epidemiology of obesity among people with HIV.
Talathi R; Anekwe CV; Toribio M
Curr Opin HIV AIDS; 2024 Jan; 19(1):1-5. PubMed ID: 37916907
[TBL] [Abstract][Full Text] [Related]
2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
3. The pathogenesis of obesity in people living with HIV.
Bailin SS; Koethe JR; Rebeiro PF
Curr Opin HIV AIDS; 2024 Jan; 19(1):6-13. PubMed ID: 37934696
[TBL] [Abstract][Full Text] [Related]
4. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.
Capeau J; Lagathu C; Béréziat V
Curr Opin HIV AIDS; 2024 Jan; 19(1):14-20. PubMed ID: 38078606
[TBL] [Abstract][Full Text] [Related]
5. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens.
Milic J; Renzetti S; Ferrari D; Barbieri S; Menozzi M; Carli F; Dolci G; Ciusa G; Mussini C; Calza S; Guaraldi G
AIDS; 2022 Oct; 36(12):1643-1653. PubMed ID: 35727163
[TBL] [Abstract][Full Text] [Related]
6. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
[TBL] [Abstract][Full Text] [Related]
7. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
[TBL] [Abstract][Full Text] [Related]
8. HIV and obesity: updates in management strategies.
Parra-Rodriguez L; O'Halloran JA
Curr Opin HIV AIDS; 2023 Mar; 18(2):68-74. PubMed ID: 36644952
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.
Guaraldi G; Calza S; Milic J; Calcagno A; Focà E; Rota M; Renzetti S; Celotti A; Siano M; Celesia BM; Piconi S; de Socio GV; Cattelan AM; Orofino G; Riva A; Nozza S; di Perri G
AIDS; 2021 May; 35(6):939-945. PubMed ID: 33635844
[TBL] [Abstract][Full Text] [Related]
10. Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus.
O'Halloran JA; Sahrmann J; Parra-Rodriguez L; Vo DT; Butler AM; Olsen MA; Powderly WG
Clin Infect Dis; 2022 Dec; 75(12):2060-2065. PubMed ID: 35521785
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy and weight gain in naive HIV-1 infected patient: a narrative review.
Dupont E; Cyr-Yombi J
AIDS Rev; 2022; 25(3):122-132. PubMed ID: 36343575
[TBL] [Abstract][Full Text] [Related]
12. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
13. Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV.
Lake JE; Trevillyan J
Curr Opin HIV AIDS; 2021 May; 16(3):148-151. PubMed ID: 33797433
[TBL] [Abstract][Full Text] [Related]
14. Gestational weight gain in persons with HIV in the United States.
Jao J; Kacanek D; Broadwell C; Jacobson DL; Chadwick EG; Williams PL; Powis KM; Haddad LB; Yee L;
AIDS; 2023 May; 37(6):883-893. PubMed ID: 36729961
[TBL] [Abstract][Full Text] [Related]
15. Diabetes in HIV: the Link to Weight Gain.
Bailin SS; Koethe JR
Curr HIV/AIDS Rep; 2023 Feb; 20(1):9-18. PubMed ID: 36418528
[TBL] [Abstract][Full Text] [Related]
16. Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus.
Asundi A; Olson A; Jiang W; Varshney SP; White LF; Sagar M; Lin NH
AIDS Res Hum Retroviruses; 2022 Mar; 38(3):208-215. PubMed ID: 34877881
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
18. Obesity and Weight Gain in Persons with HIV.
Bailin SS; Gabriel CL; Wanjalla CN; Koethe JR
Curr HIV/AIDS Rep; 2020 Apr; 17(2):138-150. PubMed ID: 32072466
[TBL] [Abstract][Full Text] [Related]
19. Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.
Mastrorosa I; Pinnetti C; Brita AC; Mondi A; Lorenzini P; Del Duca G; Vergori A; Mazzotta V; Gagliardini R; Camici M; De Zottis F; Fusto M; Plazzi MM; Grilli E; Bellagamba R; Cicalini S; Antinori A
Clin Infect Dis; 2023 Feb; 76(3):e629-e637. PubMed ID: 35982541
[TBL] [Abstract][Full Text] [Related]
20. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
